ArticleJournal of managed care & specialty pharmacy2025
Guideline adherence of xanthine oxidase inhibitor utilization to treat gout in primary care.
Article in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGouty arthritis affects 3.9% of American adults and can be effectively managed using urate-lowering therapy initiated at a low dose and titrated to achieve a serum urate of less than 6 mg/dL, the "treat-to-target" approach. This approach is often underused in primary care (PC) settings.
objectiveTo identify the proportion of patients newly prescribed a xanthine oxidase inhibitor (XOI) who have their dose titrated to achieve a serum urate (SU) of less than 6 mg/dL.
methodsThis retrospective cohort analysis used prescription orders from administrative electronic health record (EHR) databases to identify adult patients with a diagnosis of gout who were newly prescribed an XOI inhibitor by a CU Medicine PC provider. The primary endpoint was the proportion of patients prescribed an XOI who had their dose up-titrated, achieved a target SU of less than 6 mg/dL, or experienced both of these within 6 months of their first XOI prescription date. Additionally, the number of incident gout flares within 12 months was compared between groups stratified by XOI up-titration performed and achievement of SU target, adjusting for confounders using logistic regression.
resultsOf 1,600 patients evaluated, 851 met eligibility criteria. Of these, 704 (83%) were male, 649 (76%) were White, and the average age was 59 years. Within 6 months, 179 patients (21%) had their XOI dose up-titrated and 239 (28%) achieved an SU of less than 6 mg/dL; 66 patients (8%) had their XOI dose up-titrated and achieved an SU of less than 6 mg/dL within 6 months. 113 patients experienced gout flare, with SU less than 6 mg/dL associated with lower odds of flare (OR = 0.41, 0.23-0.71).
conclusionsWithin a university-based PC population, the proportion of patients newly prescribed an XOI receiving up-titration or achieving SU less than 6 mg/dL within 6 months of medication initiation is low, suggesting that a treat-to-target approach is underused.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.